Abstracts tagged "anti-TNF therapy and positron emission tomography (PET)"

Abstract Number: 1279 • 2016 ACR/ARHP Annual Meeting
Imaging of Ankylosing Spondylitis By [18f]Fluoride PET-CT to Assess Bone Formation Activity and to Monitor Anti-TNF Therapy
Stefan Bruijnen¹, Nicki Verweij², Leonie van Duivenvoorde³, Dominique Baeten⁴, Christiaan van Denderen⁵, Joost Bot⁶, Otto Hoekstra⁷, Pieter Raijmakers⁶, Irene van der Horst - Bruinsma⁸ and Conny van der Laken², ¹Dept. of Rheumtaology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ²Dept. of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵READE, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁶Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁷Nuclear medicine and PET research, VU University Medical Center, Amsterdam, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Bone formation is an important hallmark of ankylosing spondylitis (AS). Recently, we demonstrated that axial bone formation activity in AS patients can be visualized…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.